Pharma Mar Stock

Pharma Mar EBIT

The EBIT of Pharma Mar (PHM.MC) as of Aug 5, 2026 is 40.28 M EUR. In the previous year, EBIT was 6.47 M EUR — a change of 522.70% (higher).

EBIT

40.28 MEUR

YoY

522.70%

Last updated:

In 2026, Pharma Mar's EBIT was 40.28 M EUR, a 522.70% increase from the 6.47 M EUR EBIT recorded in the previous year.

The Pharma Mar EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2023
-3.83 base
Jan 1, 2024
6.47 base
Jan 1, 2025
40.28 base
Jan 1, 2026 (e)
38.97 base
Jan 1, 2027 (e)
53.76 base
Jan 1, 2028 (e)
71.02 base
Jan 1, 2029 (e)
77.85 base
Jan 1, 2030 (e)
97.36 base
YEAREBIT (M EUR)
2030 est 97.36
2029 est 77.85
2028 est 71.02
2027 est 53.76
2026 est 38.97
2025 40.28
2024 6.47
2023 -3.83
2022 44.07
2021 98.50
2020 155.94
2019 -17.77
2018 -14.07
2017 -17.84
2016 -19.45
2015 11.33
2014 20.24
2013 18.96
2012 14.57
2011 7.07
2010 -9.52
2009 -32.27
2008 -37.06
2007 -45.33
2006 -48.01
Access this data via the Eulerpool API

Pharma Mar Revenue

Pharma Mar Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
158.15 M EUR
-3.83 M EUR
1.14 M EUR
Jan 1, 2024
174.86 M EUR
6.47 M EUR
26.13 M EUR
Jan 1, 2025
221.39 M EUR
40.28 M EUR
74.99 M EUR
Jan 1, 2026 (e)
211.66 M EUR
38.97 M EUR
36.29 M EUR
Jan 1, 2027 (e)
291.95 M EUR
53.76 M EUR
99.31 M EUR
Jan 1, 2028 (e)
385.67 M EUR
71.02 M EUR
178.11 M EUR
Jan 1, 2029 (e)
422.78 M EUR
77.85 M EUR
204.60 M EUR
Jan 1, 2030 (e)
528.73 M EUR
97.36 M EUR
295.28 M EUR

Pharma Mar Margins

Pharma Mar stock margins

The Pharma Mar margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharma Mar. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharma Mar.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
93.92 %
-2.42 %
0.72 %
Jan 1, 2024
95.32 %
3.70 %
14.94 %
Jan 1, 2025
94.46 %
18.19 %
33.87 %
Jan 1, 2026 (e)
94.46 %
18.41 %
17.15 %
Jan 1, 2027 (e)
94.46 %
18.41 %
34.02 %
Jan 1, 2028 (e)
94.46 %
18.41 %
46.18 %
Jan 1, 2029 (e)
94.46 %
18.41 %
48.39 %
Jan 1, 2030 (e)
94.46 %
18.41 %
55.85 %

Pharma Mar Stock analysis

What does Pharma Mar do? Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases. Pharma Mar is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Pharma Mar's EBIT

Pharma Mar's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pharma Mar's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pharma Mar's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pharma Mar’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pharma Mar stock

EBIT of Pharma Mar is 40.28 M EUR in 2026.

EBIT of Pharma Mar changed from 6.47 M EUR to 40.28 M EUR, representing a 522.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Pharma Mar since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Pharma Mar historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Pharma Mar

All Key Metrics — Pharma Mar